Genetics, ancestry, and hypertension: Implications for targeted antihypertensive therapies

Current Hypertension Reports

Volumn 16, Issue 8, 2014, Pages

  Franceschini, Nora ^a   Chasman, Daniel I ^b   Cooper DeHoff, Rhonda M ^c   Arnett, Donna K ^d  

^a IL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Ancestry; Genetics; Genome wide association studies; Hypertension; Pharmacogenetics

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANCESTRY GROUP; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENETICS; HUMAN; HYPERTENSION; PHARMACOGENETICS; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); GENETIC PREDISPOSITION;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERTENSION;

EID: 84901734335     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0461-9     Document Type: Review

References (73)

1. Ashman JJ, Beresovsky V. Multiple chronic conditions among us adults who visited physician offices: data from the national ambulatory medical care survey, 2009. Prev Chronic Dis. 2013;10:E64.
2. Burt VL,Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the us adult population. Results from the third national health and nutrition examination survey, 1988-1991. Hypertension. 1995;25:305-13.
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2014;129:399-410.
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. (Pubitemid 35472129)
5. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165:923-8. (Pubitemid 40563240)
6. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-8. (Pubitemid 351626187)
7. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). Shep Cooperative Research group. JAMA. 1991;265:3255-64.
8. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension detection and follow-up program cooperative group. JAMA. 1979;242:2562-71.
9. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114mm Hg. JAMA. 1970;213:1143-52.
10. Staessen JA, Fagard R, Thijs L, Celis H,Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (syst-eur) Trial Investigators. Lancet. 1997;350:757-64. (Pubitemid 27387202)
11. MRC trial of treatment of mild hypertension: principal results. Medical research council working party. Br Med J (Clin Res Ed). 1985;291:97-104.
12. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J Hypertens. 1985;3:379-92.
13. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement fromkidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089-100. (Pubitemid 41623371)
14. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126:2105-14.
15. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206. (Pubitemid 37430058)
16. • Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-9. This is the largest GWAS of BP published. It identified 29 SNPs in 28 loci for BP traits and hypertension. The study comprised of 69,395 individuals of European ancestry for discovery and approximately 200,000 individuals were included in the discovery and replication samples.
17. Hopkins PN, Hunt SC. Genetics of hypertension. Genet Med. 2003;5:413-29. (Pubitemid 37492813)
18. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in wnk kinases. Science. 2001;293:1107-12. (Pubitemid 32758085)
19. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009.
20. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009.
21. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet. 2011;43:1005-11.
22. Salvi E, Kutalik Z, Glorioso N, Benaglio P, Frau F, Kuznetsova T, et al. Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial no synthase. Hypertension. 2012;59:248-55.
23. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, et al. Genome-wide association study of blood pressure extremes identifies variant near umod associated with hypertension. PLoS Genet. 2010;6:e1001177.
24. Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W, Franceschini N, et al. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. Am J Hum Genet. 2014;94:349-60.
25. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, et al. Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet. 2013;22:1663-78.
26. Johnson T, Gaunt TR, Newhouse SJ, Padmanabhan S, Tomaszewski M, Kumari M, et al. Blood pressure loci identified with a gene-centric array. Am J Hum Genet. 2011;89:688-700.
27. Johnson AD, Newton-Cheh C, Chasman DI, Ehret GB, Johnson T, Rose L, et al. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension. 2011;57:903-10.
28. • Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in East Asians. Nat Genet. 2011;43:531-8. A large GWAS of East Asians. It identified four new loci (ST7L-CAPZA1, FIGN-GRB14, ENPEP and NPR3) and a newly discovered variant near TBX3. The paper compares the effect estimates for the ICBP SNPs between European and East Asian studies.
29. Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, Ban HJ, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet. 2009;41:527-34.
30. Zhu X, Young JH, Fox E, Keating BJ, Franceschini N, Kang S, et al. Combined admixture mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: contributions from the CARe consortium. Hum Mol Genet. 2011;20(11):2285-95.
31. • Franceschini N, Fox E, Zhang Z, Edwards TL, Nalls MA, Sung YJ, et al. Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations. Am J Hum Genet. 2013;93:545-54. This is the largest GWAS of BP in African ancestry individuals. The study identified three novel loci for blood pressure traits and allelic heterogeneity in one known locus.
32. Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, Cooper R, et al. Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet. 1998;63:1839-51. (Pubitemid 30415746)
33. Okada Y, Sim X, Go MJ, Wu JY, Gu D, Takeuchi F, et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in East Asian populations. Nat Genet. 2012;44:904-9.
34. Marth GT, Yu F, Indap AR, Garimella K, Gravel S, Leong WF, et al. The functional spectrum of low-frequency coding variation. Genome Biol. 2011;12:R84.
35. Sanna S, Li B, Mulas A, Sidore C, Kang HM, Jackson AU, et al. Fine mapping of five loci associated with low-density lipoprotein cholesterol detects variants that double the explained heritability. PLoS Genet. 2011;7:e1002198.
36. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008;40:592-9. (Pubitemid 351601207)
37. Bustamante CD, Burchard EG, De la Vega FM. Genomics for the world. Nature. 2011;475:163-5.
38. Scaroni C, Biason A, Carpene G, Opocher G, Mantero F. 17-alpha-hydroxylase deficiency in three siblings: short- and long-term studies. J Endocrinol Invest. 1991;14:99-108.
39. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. 1993. Biochem Biophys Res Commun. 2012;425:548-55.
40. Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience. Med (Baltimore). 1991;70:46-66.
41. Wang H, Liu J, Liu K, Liu Y, Wang Z, Lou Y, et al. Beta1-adrenoceptor gene arg389gly polymorphism and essential hypertension risk in general population: a meta-analysis. Mol Biol Rep. 2013;40:4055-63.
42. Hunt SC, Geleijnse JM, Wu LL, Witteman JC, Williams RR, Grobbee DE. Enhanced blood pressure response to mild sodium reduction in subjects with the 235t variant of the angiotensinogen gene. Am J Hypertens. 1999;12:460-6. (Pubitemid 29238407)
43. Svetkey LP, Moore TJ, Simons-Morton DG, Appel LJ, Bray GA, Sacks FM, et al. Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study. J Hypertens. 2001;19:1949-56. (Pubitemid 33035799)
44. Wolf MB, Baynes JW. Cadmium and mercury cause an oxidative stress-induced endothelial dysfunction. Biometals. 2007;20:73-81. (Pubitemid 46292031)
45. Messner B, KnoflachM, Seubert A, Ritsch A, Pfaller K, Henderson B, et al. Cadmium is a novel and independent risk factor for early atherosclerosis mechanisms and in vivo relevance. Arterioscler Thromb Vasc Biol. 2009;29:1392-8.
46. Staessen JA, Kuznetsova T, Roels HA, Emelianov D, Fagard R. Exposure to cadmium and conventional and ambulatory blood pressures in a prospective population study. Public Health and Environmental Exposure to Cadmium Study Group. Am J Hypertens. 2000;13(2):146-156. (Pubitemid 30125637)
47. Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, Guallar E. Cadmium exposure and hypertension in the 1999-2004 National Health and Nutrition Examination Survey (NHANES). Environ Health Perspect. 2008;116(1):51-56.
48. Kottgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009;41:712-7.
49. Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, et al. Common noncoding umod gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med. 2013;19:1655-60.
50. Freedman BI,MureaM. Target organ damage in African American hypertension: role of APOL1. Curr Hypertens Rep. 2012;14:21-8.
51. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic apol1 variants with kidney disease in African Americans. Science. 2010;329:841-5.
52. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40:1185-92.
53. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175-84.
54. Sanseau P, Agarwal P, BarnesMR, Pastinen T, Richards JB, Cardon LR, et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol. 2012;30:317-20.
55. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, et al. Pharmacogenetic association of the NPPA t2238c genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA. 2008;299:296-307. (Pubitemid 351159366)
56. Luo F,Wang Y,Wang X, Sun K, Zhou X, Hui R. A functional variant of nedd4l is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension. 2009;54:796-801.
57. Manunta P, Lavery G, Lanzani C, Braund PS, Simonini M, Bodycote C, et al. Physiological interaction between alpha-adducin and wnk1-nedd4l pathways on sodium-related blood pressure regulation. Hypertension. 2008;52:366-72.
58. Svensson-Farbom P,Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, et al. A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. J Hypertens. 2011;29:388-95.
59. • Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013;62:391-7. Two recent GWAS of blood response to antihypertensive drugs.
60. Arnett DK, Claas SA. Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance. Pharmacogenomics. 2009;10:1295-307.
61. Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med. 2012;44 Suppl 1:S17-22.
62. • Gong Y, McDonough CW, Wang Z, Hou W, Cooper-DeHoff RM, Langaee TY, et al. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012;5:686-91. Two recent GWAS of blood response to antihypertensive drugs.
63. He J, Kelly TN, Zhao Q, Li H, Huang J, Wang L, et al. Genome-wide association study identifies 8 novel loci associated with blood pressure responses to interventions in Han Chinese. Circ Cardiovasc Genet. 2013;6:598-607.
64. Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, Chapman AB, Gums JG, Bailey K, et al. Genome-wide association analyses suggest nell1 influences adverse metabolic response to hctz in African Americans. Pharmacogenomics J. 2014;14:35-40.
65. Gong Y, McDonough CW, Beitelshees AL, Karnes JH, O'Connell JR, Turner ST, et al. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy. 2014;34:123-30.
66. McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, et al. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) Study. PLoS ONE 2013;8(10): e76984. doi:10.1371/journal.pone.0076984
67. Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013;23:470-8.
68. Karnes JH, Gong Y, Pacanowski MA, McDonough CW, Arwood MJ, Langaee TY, et al. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide- induced diabetes. Pharmacogenet Genomics. 2013;23:697-705.
69. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (jnc 8). JAMA. 2014;311:507-20.
70. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). JAMA. 2002;288:2981-97.
71. Luft FC, Miller JZ, Grim CE, Fineberg NS, Christian JC, Daugherty SA, et al. Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses. Hypertension. 1991;17:I102-8.
72. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27:481-90 (Pubitemid 26084617)
73. Tu W, Eckert GJ, Hannon TS, Liu H, Pratt LM, Wagner MA, et al. Racial differences in sensitivity of blood pressure to aldosterone. Hypertension. 2014.